GB201010193D0 - Medicinal use - Google Patents

Medicinal use

Info

Publication number
GB201010193D0
GB201010193D0 GBGB1010193.9A GB201010193A GB201010193D0 GB 201010193 D0 GB201010193 D0 GB 201010193D0 GB 201010193 A GB201010193 A GB 201010193A GB 201010193 D0 GB201010193 D0 GB 201010193D0
Authority
GB
United Kingdom
Prior art keywords
medicinal use
medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1010193.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Respivert Ltd
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respivert Ltd filed Critical Respivert Ltd
Priority to GBGB1010193.9A priority Critical patent/GB201010193D0/en
Publication of GB201010193D0 publication Critical patent/GB201010193D0/en
Priority to EP11728920.7A priority patent/EP2582432B1/en
Priority to PCT/GB2011/051136 priority patent/WO2011158039A1/en
Priority to JP2013514786A priority patent/JP2013530179A/ja
Priority to US13/805,552 priority patent/US9079893B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB1010193.9A 2010-06-17 2010-06-17 Medicinal use Ceased GB201010193D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB1010193.9A GB201010193D0 (en) 2010-06-17 2010-06-17 Medicinal use
EP11728920.7A EP2582432B1 (en) 2010-06-17 2011-06-17 Ureido-pyrazole derivatives for use in the treatment of rhinovirus infections
PCT/GB2011/051136 WO2011158039A1 (en) 2010-06-17 2011-06-17 Ureido-pyrazole derivatives for use in the treatment of rhinovirus infections
JP2013514786A JP2013530179A (ja) 2010-06-17 2011-06-17 呼吸器合胞体ウイルス（ｒｓｖ）感染の処置に使用するためのウレイド−ピラゾール誘導体
US13/805,552 US9079893B2 (en) 2010-06-17 2011-06-17 Ureido-pyrazole derivatives for use in the treatment of respiratory syncitial virus (RSV) infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1010193.9A GB201010193D0 (en) 2010-06-17 2010-06-17 Medicinal use

Publications (1)

Publication Number Publication Date
GB201010193D0 true GB201010193D0 (en) 2010-07-21

Family

ID=42471817

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1010193.9A Ceased GB201010193D0 (en) 2010-06-17 2010-06-17 Medicinal use

Country Status (5)

Country Link
US (1) US9079893B2 (enExample)
EP (1) EP2582432B1 (enExample)
JP (1) JP2013530179A (enExample)
GB (1) GB201010193D0 (enExample)
WO (1) WO2011158039A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA105763C2 (uk) 2007-12-19 2014-06-25 Кансер Рісерч Текнолоджі Лімітед 8-ЗАМІЩЕНІ ПІРИДО[2,3-b]ПІРАЗИНИ ТА ЇХ ЗАСТОСУВАННЯ
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
NZ706154A (en) 2010-02-01 2016-09-30 Cancer Rec Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
EP2582700B1 (en) 2010-06-17 2016-11-02 Respivert Limited Respiratory formulations containing p38 mapk inhibitors
JP2014528404A (ja) * 2011-10-03 2014-10-27 レスピバート・リミテツド ｐ３８ＭＡＰキナーゼ阻害剤としての１−ピラゾリル−３−（４−（（２−アニリノピリミジン−４−イル）オキシ）ナフタレン−１−イル）尿素
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
US9783556B2 (en) 2012-08-29 2017-10-10 Respivert Limited Kinase inhibitors
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
EP2890695A2 (en) 2012-08-29 2015-07-08 Respivert Limited Kinase inhibitors
EP2890460B1 (en) 2012-08-29 2017-02-22 Respivert Limited Kinase inhibitors
EP2925742B1 (en) 2012-11-16 2016-10-26 Respivert Limited Kinase inhibitors
WO2014140582A1 (en) 2013-03-14 2014-09-18 Respivert Limited Kinase inhibitors
MX363949B (es) 2013-04-02 2019-04-08 Topivert Pharma Ltd Inhibidor de quinasa.
US9771353B2 (en) 2013-04-02 2017-09-26 Topivert Pharma Limited Kinase inhibitors based upon N-alkyl pyrazoles
WO2015014836A1 (en) 2013-07-30 2015-02-05 Janssen R&D Ireland Substituted pyridine-piperazinyl analogues as rsv antiviral compounds
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
WO2015092423A1 (en) 2013-12-20 2015-06-25 Respivert Limited Urea derivatives useful as kinase inhibitors
EP3105222B1 (en) 2014-02-14 2018-04-11 Respivert Limited Aromatic heterocyclic compounds as antiinflammatory compounds
MA40774A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
EP3017812A1 (en) * 2014-11-06 2016-05-11 Centre National De La Recherche Scientifique (Cnrs) N1-Benzyl substituted pyrazoles as antiviral agents directed against respiratory synctical virus (RSV)
MA41614A (fr) * 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
CA3015978A1 (en) 2016-04-06 2017-10-12 Topivert Pharma Limited Kinase inhibitors
WO2018176134A1 (en) 2017-03-27 2018-10-04 HYDRO-QUéBEC Salts for use in electrolyte compositions or as electrode additives
WO2021013712A1 (en) 2019-07-19 2021-01-28 Anagenesis Biotechnologies S.A.S. Polyaromatic urea derivatives and their use in the treatment of muscle diseases
EP4029501A1 (en) 2021-01-19 2022-07-20 Anagenesis Biotechnologies Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1223924A4 (en) * 1999-09-17 2004-07-14 Smithkline Beecham Corp USE OF CSAIDS AGAINST RHINOVIRUS INFECTION
EP1609789A1 (en) 2004-06-23 2005-12-28 Eli Lilly And Company Ureido-pyrazole derivatives and their use as kinase inhibitors
BRPI0920707A2 (pt) * 2008-10-02 2015-12-29 Respivert Ltd compostos
GB0818033D0 (en) * 2008-10-02 2008-11-05 Respivert Ltd Novel compound
WO2010067130A1 (en) * 2008-12-11 2010-06-17 Respivert Limited P38 map kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
GB0921730D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
JP5787976B2 (ja) 2010-04-08 2015-09-30 レスピバート・リミテツド Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア
US9024041B2 (en) 2010-04-08 2015-05-05 Respivert Ltd. P38 MAP kinase inhibitors
EP2582700B1 (en) 2010-06-17 2016-11-02 Respivert Limited Respiratory formulations containing p38 mapk inhibitors
GB201010196D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Methods

Also Published As

Publication number Publication date
WO2011158039A1 (en) 2011-12-22
JP2013530179A (ja) 2013-07-25
WO2011158039A8 (en) 2012-04-12
EP2582432A1 (en) 2013-04-24
US9079893B2 (en) 2015-07-14
EP2582432B1 (en) 2014-11-19
US20130102607A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
GB201010193D0 (en) Medicinal use
GB201004020D0 (en) New therapeutic use
ZA201304406B (en) Inhalator
EP2377457A4 (en) MEDICAL DEVICE
EP2531153A4 (en) MEDICAL DEVICE
ZA201304158B (en) Dosage form
GB201003817D0 (en) Medical device
SG10201506840QA (en) Cytotoxicity-inducing therapeutic agent
SG10201507079WA (en) Syringe
IL221768A (en) From women
EP2371264A4 (en) MEDICAL DEVICE
AP2013006855A0 (en) Medical device
EP2654872A4 (en) AUTODILATION CANNULA
GB201005122D0 (en) Medical device
GB201015822D0 (en) Medical ruggedised case
PL2536400T3 (pl) Lek zawierający miramistin
PL2394638T3 (pl) Nowe połączenia farmaceutyczne
GB201001317D0 (en) Medicament
PL390434A1 (pl) Preparat leczniczy
GB201019774D0 (en) Medicaments
GB201021708D0 (en) Novel Therapeutic use
GB201001670D0 (en) Use
ZA201301851B (en) Pharmaceutical combinations
PL118869U1 (pl) Zasobnik medyczny
GB201015335D0 (en) Medical device improvement

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)